Cidara Therapeutics Inc (CDTX) — Cash Flow Quality Index

Latest as of March 2023: -3.62x

Cidara Therapeutics Inc (CDTX) has a Cash Flow Quality Index of -3.62x as of March 2023. Operating cash flow of $-10.90 Million is below net income of $3.01 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore CDTX cash generation efficiency to assess how effectively this company generates cash.

Cash Flow Quality Index

-3.62x

Operating CF / Net Income

Operating Cash Flow

$-10.90 Million

USD

Net Income

$3.01 Million

USD

Data as of

Mar 2023

Most recent filing

Annual Cash Flow Quality Index for Cidara Therapeutics Inc (None–None)

Year-by-year earnings quality comparison for Cidara Therapeutics Inc. For live market cap and the full company financial profile, see Cidara Therapeutics Inc market capitalisation.

Year	Quality Index	Operating CF (USD)	Net Income	YoY Change

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.